New hepatitis drug could be 'transformational': CEO
July 28, 2014 at 19:00 PM EDT
The potential market for a promising new hepatitis drug could be significant for Arrowhead Research, CEO Chris Anzalone says.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.